Show threadFreddy E Escorcia Jul 3, 2025
First up, Julia! We recruited her from the Morris’ lab at the UW Madison. During her 2 yrs, she worked across several projects, but her main project was assessed the potential of an understudied #HCC selective target for #radiotheranostics (under review) !
2/8
Show threadFreddy E Escorcia May 21, 2025

One final note: You'll notice that in the RNAseq data of PDXs/PDOs, there's another target we highlighted #DLL3, which is also expressed in SCLC and NEPC and is being pursued as a target for these cancers including #radiotheranostics

https://doi.org/10.1016/S1470-2045(24)00249-3

Show threadFreddy E Escorcia May 21, 2025
Work pursuing #GPC3 #radiotheranostics using PDX models could validate these findings and offer a much needed therapeutic option for this rare, difficult to treat cancer.
Show threadFreddy E Escorcia May 21, 2025
And when tested one of our #GPC3-selective #radiotheranostics pairs, we observed nice localization and therapeutic benefit in H660 xenograft models!
Freddy E Escorcia Nov 6, 2024

🚨 Fellow #radiotheranostics nerds 🚨

Prof. Tim Witney and I are launching a Collection focused on this very topic for NPJ Imaging

Please considering submitting! Site is live!

#radiopharmaceuticals #nucmed #radonc

Freddy E Escorcia Aug 2, 2024

At #AACR24 this year, I was tasked with presenting an overview of #radiotheranostics including what the immediate future might hold and a framework to approach it.

One natural next step is repurposing existing agents for other cancers.

1/x